Insmed Incorporated (NASDAQ:INSM) Shares Acquired by Driehaus Capital Management LLC

Driehaus Capital Management LLC boosted its stake in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 2.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 171,289 shares of the biopharmaceutical company's stock after acquiring an additional 3,859 shares during the quarter. Driehaus Capital Management LLC owned about 0.10% of Insmed worth $11,826,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC lifted its holdings in shares of Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 163 shares during the last quarter. V Square Quantitative Management LLC lifted its holdings in shares of Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 248 shares during the last quarter. Spire Wealth Management purchased a new stake in shares of Insmed during the 4th quarter valued at $47,000. Smartleaf Asset Management LLC lifted its holdings in shares of Insmed by 98.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 411 shares during the last quarter. Finally, Venturi Wealth Management LLC purchased a new stake in shares of Insmed during the 4th quarter valued at $86,000.

Insiders Place Their Bets

In other news, CEO William Lewis sold 6,830 shares of the stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $72.57, for a total transaction of $495,653.10. Following the transaction, the chief executive officer now owns 233,924 shares of the company's stock, valued at approximately $16,975,864.68. This trade represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Sara Bonstein sold 18,322 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $80.31, for a total transaction of $1,471,439.82. Following the completion of the sale, the chief financial officer now owns 118,863 shares in the company, valued at $9,545,887.53. The trade was a 13.36% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 88,232 shares of company stock worth $6,868,473 in the last 90 days. 3.00% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts recently issued reports on INSM shares. Stifel Nicolaus cut their target price on Insmed from $97.00 to $96.00 and set a "buy" rating on the stock in a research report on Friday, February 21st. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Insmed in a report on Wednesday, February 19th. Truist Financial upped their price objective on shares of Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a report on Friday, February 21st. Royal Bank of Canada reaffirmed an "outperform" rating and set a $100.00 price target on shares of Insmed in a research report on Wednesday, March 19th. Finally, Morgan Stanley increased their price target on Insmed from $85.00 to $90.00 and gave the stock an "overweight" rating in a research report on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company's stock. According to data from MarketBeat, Insmed currently has an average rating of "Moderate Buy" and a consensus target price of $94.63.

Insmed Price Performance

Shares of Insmed stock traded up $1.18 during trading on Thursday, hitting $66.79. 535,166 shares of the company were exchanged, compared to its average volume of 2,322,961. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $84.91. The stock has a market capitalization of $12.14 billion, a price-to-earnings ratio of -11.95 and a beta of 0.84. The firm has a 50 day moving average price of $71.99 and a 200 day moving average price of $73.21.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm had revenue of $92.82 million for the quarter, compared to analyst estimates of $91.63 million. During the same quarter in the previous year, the company earned ($1.06) earnings per share. The company's quarterly revenue was up 22.9% on a year-over-year basis. On average, equities analysts expect that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.